前瞻性随机化动脉粥样硬化早期评估与管理(PRE-EMPT) (PRE-EMPT)
前瞻性随机化动脉粥样硬化过早症评估与管理
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.
PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:
-
A Screening Study - Participants will be assessed for plaque by one or both of these scans.
- Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
- Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
-
A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.
- Rosuvastatin 20 mg: a cholesterol-lowering medicine
- Colchicine 0.5 mg: a medication that lowers inflammation
Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.
Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.
研究概览
地位
详细说明
The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Rachel Olson, Project Manager
- 电话号码:919-309-5544
- 邮箱:rachel.e.olson@duke.edu
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35205
- 招聘中
- University of Alabama at Birmingham
-
首席研究员:
- Kevin Riggs, MD
-
接触:
- Dalton Norwood
- 电话号码:909-786-8315
- 邮箱:daltonnorwood@uabmc.edu
-
Mobile、Alabama、美国、36608
- 招聘中
- Cardiology Associates
-
接触:
- Lynn Ward, RN BSN CCRC
- 电话号码:251-607-9797
- 邮箱:lynnward@cardassoc.com
-
首席研究员:
- Jason Cole, MD
-
-
California
-
Los Angeles、California、美国、90095
- 招聘中
- University of California, Los Angeles
-
接触:
- Lynae Edmunds
- 电话号码:310--210-9806
- 邮箱:laedmunds@mednet.ucla.edu
-
首席研究员:
- Karol Watson, MD
-
Los Angeles、California、美国、90502
- 招聘中
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
-
接触:
- Sajad Hamal
- 电话号码:310-974-9336
- 邮箱:shamal@lundquist.org
-
首席研究员:
- Matthew Budoff, MD
-
-
Georgia
-
Hiram、Georgia、美国、30141
- 招聘中
- Wellstar Kennestone Hospital
-
首席研究员:
- Frank Corrigan, MD
-
接触:
- Frank Corrigan, MD
- 电话号码:678-324-4444
- 邮箱:frank.corrigan@wellstar.org
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago
-
首席研究员:
- Tamar Polonsky, MD
-
接触:
- Tamar Polonsky, MD
- 电话号码:773-702-1409
- 邮箱:tpolonsky@bsd.uchicago.edu
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 尚未招聘
- Johns Hopkins University
-
接触:
- Prati Pratishruti, MBBS
- 电话号码:410-301-1245
- 邮箱:fpratis1@jhu.edu
-
首席研究员:
- Michael Blaha, MD
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Massachusetts General Hospital Brigham
-
接触:
- Pearl Lee, MSc
- 电话号码:617-721-7783
- 邮箱:plee23@mgh.harvard.edu
-
首席研究员:
- Michael Honigberg, MD
-
-
Minnesota
-
Duluth、Minnesota、美国、55805
- 招聘中
- Essentia Health
-
接触:
- Martha Vanderlinde, BS
- 电话号码:218-786-2729
- 邮箱:Martha.Vanderlinde@essentiahealth.org
-
首席研究员:
- Catherine Benzinger, MD
-
-
New York
-
Mount Kisco、New York、美国、10549
- 尚未招聘
- Northern Westchester Hospital
-
接触:
- Dina Katz, MD
- 电话号码:914-762-5810
- 邮箱:PRE-EMPT@northwell.edu
-
首席研究员:
- Dina Katz, MD
-
New York、New York、美国、10021
- 招聘中
- Weill Cornell Medicine
-
接触:
- Dolores Reynolds, RN
- 电话号码:212-746-4617
- 邮箱:dtr2001@med.cornell.edu
-
首席研究员:
- Sam Kim, MD
-
New York、New York、美国、10016
- 招聘中
- New York University Langone
-
首席研究员:
- Harmony Reynolds, MD
-
接触:
- Harmony Reynolds, MD
- 电话号码:212-263-4320
- 邮箱:PREEMPT@nyulangone.org
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University Hospital
-
首席研究员:
- Nishant Shah, MD
-
接触:
- Niki Huffman
- 电话号码:919-681-6458
- 邮箱:niki.huffman@duke.edu
-
Winston-Salem、North Carolina、美国、27157
- 招聘中
- Wake Forest University, Advocate Health
-
首席研究员:
- Michael Shapiro, MD
-
接触:
- Sophia Dawson, BA
- 电话号码:336-713-2338
- 邮箱:Sophia.Dawson@advocatehealth.org
-
-
Oregon
-
Portland、Oregon、美国、97239
- 尚未招聘
- Oregon Health and Sciences University
-
接触:
- John Halvorson
- 电话号码:503-418-1679
- 邮箱:halvorsj@ohsu.edu
-
首席研究员:
- Maros Ferencik, MD
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107
- 尚未招聘
- Thomas Jefferson University
-
接触:
- Caroline Freeman, BS
- 电话号码:215-792-3872
- 邮箱:Caroline.Freeman@Jefferson.edu
-
首席研究员:
- Chris Chambers, MD
-
Pittsburgh、Pennsylvania、美国、15213
- 招聘中
- University of Pittsburgh Medical Center
-
首席研究员:
- Anum Saeed, MD
-
接触:
- Karli Drewencki
- 电话号码:412-647-2931
- 邮箱:drewenckikr2@upmc.edu
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- 招聘中
- Medical University of South Carolina (MUSC)
-
首席研究员:
- Sheldon Litwin, MD
-
接触:
- Melissa Amitrano, MPH
- 电话号码:843-876-5009
- 邮箱:amitrano@musc.edu
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 尚未招聘
- Vanderbilt University
-
首席研究员:
- Deepak Gupta, MD
-
接触:
- Gabriella Davies Thoppil, MD MPH
- 电话号码:615-421-1143
- 邮箱:g.thoppil@vumc.org
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- Houston Methodist Hospital
-
接触:
- Peyton Martin
- 电话号码:443-413-6350
- 邮箱:knasir@houstonmethodist.org
-
首席研究员:
- Khurrrram Nasir, MD
-
-
Virginia
-
Charlottesville、Virginia、美国、22903
- 招聘中
- University of Virginia (UVA)
-
接触:
- James Ingersoll
- 电话号码:434-982-1058
- 邮箱:WFC5KC@uvahealth.org
-
首席研究员:
- Todd Villines, MD
-
Fairfax、Virginia、美国、22031
- 尚未招聘
- Inova Health System
-
接触:
- Mahira Awan
- 电话号码:571-472-8570
- 邮箱:mahira.awan@inova.org
-
首席研究员:
- Jared Spitz, MD
-
-
Wisconsin
-
Marshfield、Wisconsin、美国、54449
- 招聘中
- Marshfield Clinical Research Institute
-
接触:
- Kelly Scheffen
- 电话号码:715-221-7285
- 邮箱:preempt@marshfieldresearch.org
-
首席研究员:
- Jeff VanWormer
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Women aged 40-60 years; Men aged 30-50 years
- Willing and able to provide informed consent and comply with study procedures
- Smart phone user
- Use of highly effective contraception by females with reproductive potential.
- CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
- Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab
Exclusion Criteria:
- Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
- Current symptoms thought to be from CAD
- PREVENT ASCVD 10-year risk ≥5% (if known)
- Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
- LDL-C ≥190mg/dL (most recent, if known)
- HIV (if known)
- Severe liver disease or untreated Hepatitis C infection (if known)
- Pregnancy, lactation or intending to become pregnant during the study period of 2 years
- eGFR <45mL/min/1.73m2 (if known)
- AST or ALT >1.5x the upper limit of normal (if known)
- BMI>40kg/m2 or unable to have a CCTA scan for any reason
- Allergy to iodinated intravenous contrast or other contraindication to CCTA
- Current or previous use of lipid lowering therapy or colchicine
- Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
- Systemic cancer undergoing active treatment
- PREVENT ASCVD 10-year risk ≥5%
- eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
- Hemoglobin A1c ≥6.5% per baseline labs
- LDL-C ≥190mg/dL per baseline labs
- Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
- Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
- Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:阶乘赋值
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:rosuvastatin 20mg plus colchicine-matched placebo
statin plus placebo (two pills once daily) |
Statin
其他名称:
Placebo, non-active, drug-matched |
|
实验性的:colchicine 0.5mg plus rosuvastatin-matched placebo
anti-inflammatory plus placebo (two pills once daily) |
Placebo, non-active, drug-matched Anti-inflammatory
其他名称:
|
|
实验性的:rosuvastatin 20mg plus colchicine 0.5mg
statin plus anti-inflammatory (two pills once daily) |
Statin
其他名称:
Anti-inflammatory
其他名称:
|
|
安慰剂比较:placebo plus placebo
Placebo and placebo (two pills once daily) |
Placebo, non-active, drug-matched |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
大体时间:2 years
|
Plaque volume in mm3 in each group |
2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
LDL-C(低密度脂蛋白胆固醇)变化
大体时间:基线至2年
|
基线至2年
|
|
|
非高密度脂蛋白胆固醇变化
大体时间:基线至2年
|
基线至2年
|
|
|
Number of participants with Drug Discontinuation
大体时间:Up to 2 years
|
Drug Tolerability outcome |
Up to 2 years
|
|
Overall drug treatment adherence
大体时间:Up to 2 years
|
Number of days on study drugs |
Up to 2 years
|
|
Safety events of special interest
大体时间:Up to 2 years
|
Number of safety events of special interest per group |
Up to 2 years
|
|
Total plaque volume
大体时间:Up to 2 years
|
Plaque volume in mm3 per group |
Up to 2 years
|
|
Low-attenuation plaque volume
大体时间:Up to 2 years
|
Low attenuated plaque volume in mm3 per group |
Up to 2 years
|
|
Calcified plaque volume
大体时间:Up to 2 years
|
Calcified plaque volume in mm3 per group |
Up to 2 years
|
|
Number of participants with stenosis
大体时间:Up to 2 years
|
Number of participants with stenosis per group |
Up to 2 years
|
|
Segment involvement score
大体时间:Up to 2 years
|
Average score per group |
Up to 2 years
|
|
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
大体时间:Up to 2 years
|
Number of participants with each plaque composition description per group |
Up to 2 years
|
|
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
大体时间:Up to 2 years
|
Number of participants with each plaque feature (high-risk) per group |
Up to 2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Pro00118744
- UG3HL181434 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.